Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Accenture
Medtronic
Cantor Fitzgerald
Cipla
UBS
Dow
Moodys

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206947

« Back to Dashboard

NDA 206947 describes LENVIMA, which is a drug marketed by Eisai Inc and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the LENVIMA profile page.

The generic ingredient in LENVIMA is lenvatinib mesylate. One supplier is listed for this compound. Additional details are available on the lenvatinib mesylate profile page.
Summary for 206947
Tradename:LENVIMA
Applicant:Eisai Inc
Ingredient:lenvatinib mesylate
Patents:3
Pharmacology for NDA: 206947
Suppliers and Packaging for NDA: 206947
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947 NDA Eisai Inc. 62856-708 N 62856-708-30
LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947 NDA Eisai Inc. 62856-710 N 62856-710-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 4MG BASE
Approval Date:Feb 13, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:May 13, 2019
Regulatory Exclusivity Use:EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.
Regulatory Exclusivity Expiration:Feb 13, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Feb 13, 2022
Regulatory Exclusivity Use:TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
UBS
Daiichi Sankyo
McKinsey
Covington
Chubb
Dow
Argus Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.